PIK3CA is the most frequently mutated oncogene in human cancers. Dr. Wang will present two projects that translate bench discoveries made in his laboratory into clinical trials to treat PIK3CA mutant colorectal cancer patients. The first approach targets glutamine addiction of PIK3CA mutant colorectal cancer, whereas the second approach combines drugs that target epigenetics and PI3K alpha.